Global Tumor Necrosis Factor Inhibitors Drug Market Dosage Price and Clinical Pipeline Outlook 2024

Download Sample

For Report Sample Contact: neeraj@kuickresearch.com

Report Weblink:https://www.kuickresearch.com/report-global-tumor-necrosis-factor-inhibitors-drug-market-dosage-price-and-clinical-pipeline-outlook-2024.php

Table of Contents

1. Tumor Necrosis Factor : An Overview
1.1 Prologue to Tumor Necrosis Factor
1.2 History and Discovery of Tumor Necrosis Factors

2. Significance of Tumor Necrosis Factor
2.1 TNF in Cell Signaling and Immunity
2.1.1 Tumor Necrosis Factor Receptor 1
2.1.2 Tumor Necrosis Factor Receptor 2
2.2 Role of TNF in Cancer
2.3 Disease Related to TNF and Members of Its Family

3. Working Mechanism of Tumor Necrosis Factors (TNF) Inhibitors and Their Therapeutic Evolution
3.1 Tumor Necrosis Factor and Immune Response
3.2 Tumor Necrosis Factor Inhibition by Monoclonal Antibodies

4. Approaches Used in Development of TNF Inhibitors
4.1 Monoclonal Antibody Approach
4.2 Recombinant DNA Technology Approach

5. Global Tumor Necrosis Factor Alpha Inhibitors Pipeline Overview

6. Global Tumor Necrosis Factor Alpha Inhibitors Clinical Pipeline by Company, Indication and Phase
6.1 Unknown
6.2 Research
6.3 Preclinical
6.4 Clinical
6.5 Phase-I
6.6 Phase-I/II
6.7 Phase-II
6.8 Phase-II/III
6.9 Phase-III
6.10 Preregistration
6.11 Registered

7. Marketed Global Tumor Necrosis Factor Alpha Inhibitors Clinical Insight by Company and Indication
7.1 Golimumab (Shinponi, Simponi, Simponi Aria, Simponi I.V, Sympony and Symposony)
7.2 Pomalidomide (Imnovid and Pomalyst)
7.3 Adalimumab (Humira and Raheara)
7.4 Infliximab (Remicade)
7.5 Certolizumab Pegol (CIMZIA AutoClicks Prefilled Pen, Cimzia and Simziya)
7.6 Apremilast (Otezla)
7.7 Infliximab Biosimilar - Celltrion
7.8 Lumbricus Rubellus Extract (Inflectra and Remsima)
7.9 Adalimumab Biosimilar (AdaliRel and Adfrar)
7.10 Infliximab Biosimilar (Infimab)
7.11 Infliximab Biosimilar - Bionovis/ The Instituto Vital Brazil
7.12 Adalimumab Biosimilar (Exemptia)
7.13 Anti-Tumour Necrosis Factor-Alpha Antibody Oral

8. Price, Dosage and Treatment Cost Analysis of Commercially Available TNF Based Therapeutics
8.1 Cimzia (Certolizumab Pegol)
8.2 Enbrel (Etanercept)
8.2.1 Benepali andndash; Etanercept Biosimilar
8.3 Humira ( Adalimumab)
8.3.1 Amjevita andndash; Humira Biosimilar
8.3.2 Cyltezo andndash; Second Biosimilar to Humira
8.4 Otezla (Apremilast)
8.5 Remicade (Infliximab)
8.5.1 Remsima - Infliximab Biosimilar
8.5.2 Inflectra andndash; Infliximab Biosimilar
8.6 Simponi (Golimumab)

9. Current Market Trends and Recent Advances in the TNF Inhibitors Segment
9.1 Dominance of TNF Inhibitors in Global Therapeutics Market
9.2 Global TNF Inhibitor Market by Indication andndash; Market Size and Growing Opportunity
9.2.1 Rheumatoid Arthritis
9.2.2 Psoriasis and psoriatic arthritis (PsA)
9.2.3 Crohn’s Disease
9.2.4 Ankylosing Spondylitis
9.3 Global TNF Inhibitors Market by Region
9.3.1 US
9.3.2 Europe
9.3.3 Asia- Pacific
9.3.4 Middle East and Africa (MEA)

10. TNF Inhibitor- Sales and Patent Analysis
10.1 TNF Inhibitor Market by Sales
10.1.1 Cimzia
10.1.2 Enbrel
10.1.3 Humira
10.1.4 Remicade
10.2 TNF Inhibitor Market by Approvals and Patent
10.3 TNF Inhibitor Biosimilar Sales Analysis

11. TNF Inhibitors Market Driving Parameters

12. Restraining Factors of the Global TNF Inhibitors Market

13. Global TNF Inhibitors Future Forecast and Sales Projections
13.1 Impact of Biosimilar ‘Benepali’ on Enbrel Sales
13.2 Affordable Alternatives to Humira and Their Effect on Global Humira Sales
13.3 Remicade and Its Biosimilar
13.4 Conclusion and Executive Summary

14. Competitive Landscape
14.1 AbbVie
14.2 Ablynx
14.3 Apogenix
14.4 AryoGen Biopharma
14.5 Bionovis
14.6 CASI Pharmaceuticals
14.7 Celltrion
14.8 Celgene Corporation
14.9 Delenex Therapeutics
14.10 Dexa Medica
14.11 EPIRUS Biopharmaceuticals
14.12 Janssen Biotech
14.13 GlaxoSmithKline
14.14 HanAll Biopharma
14.15 Intas Pharmaceuticals
14.16 LEO Pharma
14.17 LG Life Sciences
14.18 MedImmune
14.19 Momenta Pharmaceuticals
14.20 Novartis
14.21 PROBIOMED
14.22 Reliance Life Sciences
14.23 Sandoz
14.24 Samsung Bioepis
14.25 Sanofi-Aventis
14.26 Shanghai CP Guojian Pharmaceutical
14.27 Shanghai Pharmaceuticals
14.28 Simcere Pharmaceutical
14.29 Toyama Chemical
14.30 Tsumura
14.31 UCB
14.32 Zydus Cadila

Figure 1-1: Multiple Roles of TNF
Figure 1-2: Historical timeline of Tumor Necrosis Factor
Figure 1-3: Historical Timeline of Tumor Necrosis Factor Inhibitors
Figure 2-1: TNF Factor Types and Their Inhibition
Figure 2-2: Diseases Related to TNF and Its Family Members
Figure 3-1: General Working Mechanism of TNF Inhibitors
Figure 5-1: Global Tumor Necrosis Factor Alpha Inhibitors Pipeline by Phase (%), 2018 till 2024
Figure 5-2: Global Tumor Necrosis Factor Alpha Inhibitors Pipeline by Phase (Number), 2018 till 2024
Figure 5-3: Global Tumor Necrosis Factor Alpha Inhibitors Pipeline by Phase (%),2018 till 2024
Figure 5-4: Global Tumor Necrosis Factor Alpha Inhibitors Pipeline by Phase (Number), 2018 till 2024
Figure 8-1: Cimzia - Dose for Crohn's Disease (mg/week)
Figure 8-2: Cimzia - Dose for Rheumatoid Arthritis (US$)
Figure 8-3: Cimzia - Dose for Psoriatic Arthritis (mg)
Figure 8-4: Cimzia - Dose for Ankolysing Spondylitis (mg)
Figure 8-5: Cimzia (Certolizumab Pegol) andndash; Average Price (US$)
Figure 8-6: Cimzia - Treatment Cost Analysis, 2018
Figure 8-7: TNF inhibition by Enbrel, Working Mechanism
Figure 8-8: Enbrel - Dosage Forms and Strength (mg and ml)
Figure 8-9: Enbrel - Dosage and Frequency for Arthritis, AS and PsA (mg/Week)
Figure 8-10: Enbrel - Dose for Juvenile Idiopathic Arthritis (mg and mg/kg)
Figure 8-11: Enbrel - Subcutaneous Kit Price (US$/Unit), 2018
Figure 8-12: Enbrel - Prefilled Syringe Price (US$/Vial), 2018
Figure 8-13: Global - Enbrel Price by Region (US$)
Figure 8-14: Enbrel - Treatment Cost Analysis (US$/Month)
Figure 8-15: Enbrel - Price per QALY Gained (US$), 2018
Figure 8-16: Humira - Mechanism of Action
Figure 8-17: Humira - Dosage Analysis by Indication (mg)
Figure 8-18: Humira - Dosage Analysis for Crohn's Disease (mg)
Figure 8-19: Humira andndash; Dose for Plaque Psoriasis (mg)
Figure 8-20: Humira - Subcutaneous Kit Price (US$), 2017
Figure 8-21: Humira - Average Treatment Cost Analysis per Month (US$), 2017
Figure 8-22: Otezla - Dose for Plaque Psoriasis
Figure 8-23: Otezla - Price Analysis (US$/Unit), 2017
Figure 8-24: Remicade (Infliximab)- Mode of Action
Figure 8-25: Remicade - Dose for Crohn's Disease (mg/kg)
Figure 8-26: Remicade - Dose for Rheumatoid Arthritis (mg/kg)
Figure 8-27: Remicade- Price Analysis for 100mg Vial (US$), 2018
Figure 8-28: Simponi - Availability by Concentration (mg/0.5ml)
Figure 8-29: Simponi - Dosage Analysis (mg)
Figure 8-30: Simponi - Price Analysis (US$/ml), 2018
Figure 9-1: Global- Therapeutics Market Segmentation by size (%)
Figure 9-2: Global - Rheumatoid Arthritis Prevalence (per 100,000 Individuals), 2016-2017
Figure 9-3: Global - Psoriasis and Psoriatic Arthritis Prevalence, 2015-2016
Figure 9-4: Global- Crohn's Disease Epidemiology (per 100,000 Individuals), 2012-2017
Figure 9-5: Global - Ankylosing Spondylitis (per 100,000 Individuals), 2018
Figure 9-6: US - TNF inhibitors Market by Prevalence of Indication (per 1000 Individuals) , 2017
Figure 9-7: Humira Cost Analysis by Region- US v/s India (US$/Vial), 2017
Figure 10-1: Global- Cimzia Sales (US$ Million), 2016 and 2017
Figure 10-2: Global - Enbrel Sales (US$ Million), 2014-2017
Figure 10-3: Global- Humira Sales (US$ Million), 2014-2017
Figure 10-4: Global- Remicade Sales (US$ Million), 2014-2017
Figure 10-5: Global - TNF Inhibitors Patent by Number
Figure 10-6: Patent Analysis - Patent Expiration by Year
Figure 10-7: Global - TNF Inhibitor Biosimilar Sales (US$ Million), 2015-2017
Figure 10-8: Global - Benepali Sales (US$ Million), 2016-2017
Figure 11-1: Driving Factors of the TNF Inhibitors Segment
Figure 12-1: Challenging Factors of the TNF Inhibitors Market
Figure 13-1: Global andndash; Enbrel Sales Future Forecast (US$ Million), 2017-2024
Figure 13-2: Global - Humira Sales Forecast (US$ Million), 2017-2024
Figure 13-3: Global - Amjevita Sales Future Forecast (US$ Million), 2020 and 2024
Figure 13-4: Global - Remicade Future Sales Forecast (US$ Million), 2016-2024
Figure 13-5: Global - Blockbuster TNF Inhibitors Sales (US$ Billion), 2017
Figure 14-1: Ablynx - Clinical Pipeline
Figure 14-2: Apogenix - Clinical Pipeline
Figure 14-3: Casi Pharmaceutical - Clinical Pipeline
Figure 14-4: Celgene - Clinical Pipeline
Figure 14-5: EPIRUS Biopharmaceuticals - Clinical Pipeline
Figure 14-6: HanAll Biopharma - Clinical Pipeline
Figure 14-7: Novartis - Clinical Pipeline
Figure 14-8: Sandoz - Clinical Pipeline
Figure 14-9: Toyama Chemical - Clinical Pipeline
Figure 14-10: Zydus Cadila - Clinical Pipeline

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
+91-11-47067990

This release was published on openPR.